Literature DB >> 18175148

Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin.

Masaru Miura1, Kazuki Kohno, Hirotaka Ohki, Shigeki Yoshiba, Akinori Sugaya, Masaaki Satoh.   

Abstract

This study aimed to determine the effects of intravenous methylprednisolone pulse (IVMP) therapy on cytokine levels in patients with acute Kawasaki disease (KD) unresponsive to initial intravenous immunoglobulin (IVIG) therapy. Fifteen KD patients unresponsive to initial IVIG, 2 g/kg/day, were randomized to receive IVMP (n = 7), 30 mg/kg/day for 3 days or additional IVIG (n = 8), 2 g/kg/day, and plasma cytokine levels were compared. The fraction of febrile patients was significantly lower in the IVMP group than in the additional IVIG group on day 2 (0/7 vs. 3/8, p = 0.03), but not on day 4 and later (3/7 vs. 4/8, p = 1.00) because of recurrent fever. The prevalence of coronary lesions was similar between the two groups (2/7 vs. 2/8, p = 1.00). The ratios of plasma levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 to those at enrollment (defined as day 1) were significantly lower in the IVMP group on day 4 (0.50 +/- 0.27 vs. 1.01 +/- 0.46, 0.53 +/- 0.39 vs. 0.93 +/- 0.44, p = 0.02 and 0.045, respectively), but not on day 7 (0.54 +/- 0.34 vs. 0.88 +/- 0.39, 0.76 +/- 0.39 vs. 0.61 +/- 0.17, p = 0.07 and 0.83, respectively). The ratios of interleukin-2 receptor, interleukin-6, and vascular endothelial cell growth factor to those at enrollment did not differ significantly between the two groups. In conclusion, for KD patients unresponsive to initial IVIG, IVMP suppresses cytokine levels faster, but subsequently similarly, compared with additional IVIG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175148     DOI: 10.1007/s00431-007-0642-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  16 in total

1.  Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis.

Authors:  P P Youssef; D R Haynes; S Triantafillou; A Parker; J R Gamble; P J Roberts-Thomson; M J Ahern; M D Smith
Journal:  Arthritis Rheum       Date:  1997-08

2.  Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease.

Authors:  M Miura; H Ohki; S Yoshiba; H Ueda; A Sugaya; M Satoh; H Yamagishi
Journal:  Arch Dis Child       Date:  2005-10       Impact factor: 3.791

3.  Pharmacological aspects of corticosteroid pulse therapy.

Authors:  P J Pentikäinen
Journal:  Scand J Rheumatol Suppl       Date:  1984

4.  Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment.

Authors:  M Terai; T Jibiki; A Harada; Y Terashima; K Yasukawa; S Tateno; H Hamada; S Oana; H Niimi; K Matsushima
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

5.  Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors:  Jane W Newburger; Lynn A Sleeper; Brian W McCrindle; L LuAnn Minich; Welton Gersony; Victoria L Vetter; Andrew M Atz; Jennifer S Li; Masato Takahashi; Annette L Baker; Steven D Colan; Paul D Mitchell; Gloria L Klein; Robert P Sundel
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

6.  Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.

Authors:  K Hashino; M Ishii; M Iemura; T Akagi; H Kato
Journal:  Pediatr Int       Date:  2001-06       Impact factor: 1.524

7.  Infliximab treatment for refractory Kawasaki syndrome.

Authors:  Jane C Burns; Wilbert H Mason; Sarmistha B Hauger; Hillel Janai; John F Bastian; Julie D Wohrley; Ian Balfour; Cynthia A Shen; Edward D Michel; Stanford T Shulman; Marian E Melish
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

8.  Effects of pulse methylprednisolone on macrophage chemotactic protein-1 and macrophage inflammatory protein-1alpha in rheumatoid synovium.

Authors:  P K Wong; C Cuello; J V Bertouch; P J Roberts-Thomson; M J Ahern; M D Smith; P P Youssef
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

9.  Cytokines predict coronary aneurysm formation in Kawasaki disease patients.

Authors:  C Y Lin; C C Lin; B Hwang; B N Chiang
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

10.  Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids.

Authors:  D A Wright; J W Newburger; A Baker; R P Sundel
Journal:  J Pediatr       Date:  1996-01       Impact factor: 4.406

View more
  12 in total

Review 1.  Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease.

Authors:  Seyyedeh Saneeymehri; Katherine Baker; Tsz-Yin So
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

2.  Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy.

Authors:  Masaru Miura; Takuya Tamame; Takashi Naganuma; Shino Chinen; Megumi Matsuoka; Hirotaka Ohki
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

Review 3.  Corticosteroids for the treatment of Kawasaki disease in children.

Authors:  Jessica Green; Andrew J Wardle; Robert Mr Tulloh
Journal:  Cochrane Database Syst Rev       Date:  2022-05-27

4.  Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study.

Authors:  Masayuki Teraguchi; Hirotaro Ogino; Ken Yoshimura; Shoichiro Taniuchi; Minoru Kino; Hitoshi Okazaki; Kazunari Kaneko
Journal:  Pediatr Cardiol       Date:  2012-11-27       Impact factor: 1.655

Review 5.  Corticosteroids for the treatment of Kawasaki disease in children.

Authors:  Andrew J Wardle; Georgia M Connolly; Matthew J Seager; Robert Mr Tulloh
Journal:  Cochrane Database Syst Rev       Date:  2017-01-27

6.  A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.

Authors:  Bo-Hui Zhu; Hai-Tao Lv; Ling Sun; Jian-Min Zhang; Lei Cao; Hong-Liang Jia; Wen-Hua Yan; Yue-Ping Shen
Journal:  Eur J Pediatr       Date:  2011-11-05       Impact factor: 3.183

Review 7.  IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease.

Authors:  Perrine Dusser; Isabelle Koné-Paut
Journal:  Front Pharmacol       Date:  2017-03-28       Impact factor: 5.810

Review 8.  Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.

Authors:  Han Chan; Huan Chi; Hui You; Mo Wang; Gaofu Zhang; Haiping Yang; Qiu Li
Journal:  BMC Pediatr       Date:  2019-05-17       Impact factor: 2.125

9.  Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease.

Authors:  Chun-Na Zhao; Zhong-Dong Du; Ling-Ling Gao
Journal:  Chin Med J (Engl)       Date:  2016-04-20       Impact factor: 2.628

10.  Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease.

Authors:  Hyejin Jang; Kyu Yeun Kim; Dong Soo Kim
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.